last
year
unit
state
approxim
children
diagnos
cancer
children
underw
solid
organ
transplant
sot
children
underw
hematopoiet
cell
transplant
hct
increasingli
broad
set
lifethreaten
diseas
signific
progress
made
improv
safeti
antineoplast
transplantationbas
therapi
risk
infecti
complic
remain
high
particular
lower
respiratori
tract
infect
children
undergon
hct
associ
mortal
rate
exceed
current
microbiolog
diagnost
inadequ
fail
identifi
pathogen
organ
one
third
case
autopsi
case
seri
identifi
previous
undetect
pulmonari
pathogen
pediatr
hct
patient
underscor
current
diagnost
limit
signific
mortal
associ
undiagnos
pulmonari
infect
patient
recent
advanc
metagenom
next
gener
sequenc
mng
shown
promis
result
diagnos
neurolog
ocular
infect
howev
identif
fastidi
pathogen
aspergillu
filament
mold
remain
difficult
due
thick
extracellular
matric
rel
small
inoculum
requir
induc
diseas
unfortun
offtheshelf
assay
respiratori
biospecimen
proven
inadequ
survey
varieti
organ
present
thick
mucoid
respiratori
secret
unlik
bettercharacter
microbiom
human
gastrointestin
tract
nasopharynx
data
describ
composit
pulmonari
microbiom
spars
insuffici
reliabl
discrimin
health
diseas
therefor
conduct
pilot
studi
aim
develop
optim
highli
sensit
mng
assay
capabl
detect
pulmonari
bacteri
fungal
viral
pathogen
clinic
relev
immunocompromis
children
test
mng
assay
cohort
immunocompromis
children
undergo
lower
respiratori
tract
sampl
evalu
suspect
pulmonari
infect
hypothes
optim
mng
assay
could
improv
character
pulmonari
microbiom
aid
identif
potenti
pulmonari
pathogen
highrisk
popul
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
laboratori
previous
character
highthroughput
mng
protocol
use
human
cerebrospin
intravitr
fluid
given
challeng
diagnos
pulmonari
infect
creat
set
mockposit
bal
spike
predetermin
number
coloni
form
unit
cfu
aspergillu
niger
clinic
isol
aliquot
bal
previous
identifi
haemophilu
influenzaehuman
adenoviru
b
coinfect
supplement
text
aspergillu
chosen
optim
benchmark
given
thick
polysaccharid
cell
wall
extrem
clinic
import
patient
popul
bioinformat
pipelin
result
fastq
file
process
use
previous
describ
pipelin
consist
sever
opensourc
compon
briefli
read
underw
iter
remov
host
low
qualiti
low
complex
lzw
compress
ratio
redund
sequenc
use
star
priceseqfilt
cdhitdup
remain
sequenc
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
align
ncbi
nonredund
nucleotid
databas
use
gsnapl
assign
bacteri
fungal
viral
taxonom
id
microb
describ
potenti
pathogen
typic
nonpathogen
base
priori
literatur
review
supplement
text
avoid
spuriou
align
sequenc
artifact
includ
read
pair
end
align
taxonom
id
preval
microb
describ
rel
microb
sampl
wherein
normal
sequenc
read
per
million
total
sequenc
read
rpm
rel
microb
sampl
cohort
wherein
normal
sequenc
read
number
standard
deviat
mean
rpm
total
cohort
zscore
outlier
defin
microb
rna
align
abund
within
sampl
bacteri
read
sampl
rpm
fungi
virus
standard
deviat
cohort
mean
particular
microb
zscore
subset
outlier
confirm
via
orthogon
assay
simpson
divers
index
use
associ
loss
bacteri
divers
presenc
outlier
microb
detail
method
supplement
text
sequenc
read
deposit
ncbi
dbgap
bioproject
id
test
optim
mng
assay
prospect
collect
lower
respiratori
sampl
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
iter
optim
demonstr
mechan
homogen
bal
use
inert
bash
bead
cycl
dnarna
shield
without
mycolyt
enzym
superior
approach
isol
microbi
nucleic
acid
supplement
text
supplement
figur
aspergillu
comparison
optim
dna
sequenc
assay
abl
detect
aspergillu
cfu
ci
suggest
rnaseq
approxim
sensit
dnaseq
detect
aspergillu
nucleic
acid
respiratori
specimen
pair
ttest
p
figur
optim
chang
detect
hinfluenza
human
adenoviru
b
ttest
respect
result
suggest
optim
rnaseq
protocol
suffici
dynam
rang
detect
aspergillu
nucleic
acid
quantiti
analog
rare
growth
cultur
enrol
patient
collect
lower
respiratori
sampl
pilot
project
tabl
use
optim
extract
protocol
describ
conduct
mng
result
million
read
per
sampl
qualiti
filter
remov
human
read
remain
read
align
bacteria
fungi
virus
analyz
discuss
detail
report
patient
exist
appendix
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
fungi
rel
bacteri
align
fungal
align
significantli
less
preval
cohort
fungal
genera
detect
less
singl
read
per
million
read
map
figur
approxim
half
identifi
fungal
genera
low
abund
present
level
similar
sampl
cohort
addit
low
abund
rare
cohort
evid
support
align
limit
rariti
read
fungal
genera
abund
zscore
outlier
includ
potenti
pathogen
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
fungi
identifi
total
time
patient
sampl
alternaria
aspergillu
candida
cladsoporium
cryptococcu
fusarium
pneumocysti
next
contextu
burden
aspergillu
sampl
estim
number
aspergillu
cfu
accord
linear
regress
associ
aspergillu
cfu
rna
transcript
deriv
spikein
experi
aspergillu
rna
level
correl
cfu
sampl
suggest
lower
airway
immunocompromis
children
frequent
expos
quantiti
aspergillu
rna
consist
low
number
cfu
sampl
one
patient
sampl
posit
ipa
cultur
galactomannan
assay
figur
label
although
remain
cultureneg
receiv
fungicid
fungistat
antiaspergillu
pharmacotherapi
within
hour
sampl
collect
suggest
empir
antifung
pharmacotherapi
significantli
confound
associ
aspergillu
rna
growth
cultur
aspergillu
rna
sequenc
read
correl
growth
cultur
ttest
correl
bal
galactomannan
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
addit
two
patient
viral
coinfect
influenzac
approxim
half
viral
genera
detect
read
per
million
sequenc
read
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
mycoplasmaspecif
pcr
bacteri
fungal
amplicon
sequenc
supplement
text
valid
test
concord
mng
one
except
amplicon
dna
sequenc
fail
identifi
cglabrata
sampl
sampl
confirm
presenc
organ
separ
speciesspecif
rtpcr
primer
set
follow
sanger
sequenc
inhous
confirm
initi
mng
report
cglabrata
numer
complementari
bioinformat
approach
analyz
metagenom
dataset
test
reproduc
approach
reanalyz
data
use
parallel
method
develop
inhous
weight
organ
abund
concord
pair
rna
dna
sequenc
read
without
zscore
supplement
tabl
result
analyt
approach
primari
analyt
approach
show
strong
agreement
sum
data
demonstr
mng
significantli
greater
sensit
detect
potenti
pulmonari
pathogen
current
clinic
diagnost
mcnemar
p
studi
develop
optim
mng
assay
adequ
sensit
identifi
bacteria
fungi
rna
dna
virus
within
lower
respiratori
tract
immunocompromis
children
identifi
rich
molecular
portrait
pulmonari
microbiom
vulner
patient
popul
compar
quantiti
microbi
nucleic
acid
microb
within
sampl
sampl
within
cohort
abl
identifi
outli
potenti
pathogen
approxim
half
previouslyneg
sampl
due
inher
challeng
sampl
lower
respiratori
tract
pulmonari
microbiom
one
origin
site
sampl
human
microbiom
project
data
regard
pulmonari
microbi
commun
health
diseas
lag
decad
behind
similar
analys
human
intestin
cutan
nasopharyng
microbiom
studi
detect
mani
pathogen
bacteria
pseudomona
streptococcu
ubiquit
henc
abund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
need
contextu
cohortspecif
norm
use
cohortspecif
zscore
provid
templat
discrimin
normal
abnorm
microbi
burden
lung
immunocompromis
children
exampl
sampl
detect
pseudomona
rna
sampl
detect
pseudomona
rna
standard
deviat
cohort
mean
appendix
prior
metagenom
sequenc
assay
human
biospecimen
demonstr
excel
detect
viral
bacteri
nucleic
acid
lack
sensit
detect
fastidi
organ
filament
mold
studi
confirm
need
aggress
mechan
homogen
stabil
media
order
detect
mold
aspergillu
simultan
preserv
detect
bacteria
virus
despit
transcript
align
fungi
remain
significantli
less
ubiquit
transcript
align
bacteria
perhap
due
rel
organ
abund
although
major
commerci
sequenc
assay
use
dna
data
demonstr
rna
sequenc
time
sensit
dna
sequenc
detect
fastidi
organ
specul
may
due
high
transcript
activ
region
rrna
gene
activ
organ
surprisingli
aspergillu
rna
equival
cfu
detect
sampl
water
control
suggest
lung
immunocompromis
children
frequent
expos
low
level
aspergillu
increas
aspergillu
nucleic
acid
optim
mechan
homogen
suggest
origin
aspergillu
rna
like
intact
fungal
organ
lower
respiratori
tract
immunocompromis
children
rather
migrat
extracellular
nucleic
acid
respiratori
tree
howev
sampl
origin
patient
suspect
ipa
specul
patientspecif
factor
immun
reconstitut
alloreact
inflamm
impair
mucociliari
clearanc
import
inoculum
exposur
determin
child
might
develop
ipa
although
aspergillu
growth
cultur
appear
confound
frequent
use
prophylact
empir
antifung
quantiti
aspergillu
sequenc
read
correl
bal
galactomannan
nutrient
avail
kinet
aspergillu
growth
may
affect
galactomannan
releas
bioavail
aspergillu
nucleic
acid
advoc
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
rnadnabas
assay
might
complement
replac
antigenbas
assay
diagnosi
ipa
mng
assay
highli
sensit
aspergillu
detect
specif
differenti
infect
colon
limit
futur
studi
pair
mng
host
suscept
immun
function
may
improv
discrimin
colon
invas
mycosi
consist
emerg
data
pediatr
work
also
detect
herpesvirus
cmv
low
abund
across
mani
children
cohort
interestingli
number
typic
nonpathogen
virus
torquetenoviru
ki
polyomaviru
present
half
cohort
data
support
direct
pathogen
virus
lack
may
marker
immun
function
predictor
posttranspl
infecti
alloimmun
complic
includ
lung
injuri
gener
futur
studi
aim
character
longitudin
chang
pulmonari
virom
immunocompromis
children
warrant
character
distribut
pulmonari
microb
within
cohort
abl
identifi
statist
outli
potenti
pathogen
half
previous
neg
sampl
cultiv
bacteria
fungi
detect
clinic
isol
patient
alreadi
receiv
antimicrobi
therapi
highlight
import
cultureindepend
techniqu
addit
sever
pathogen
virus
detect
clinic
due
omiss
multiplex
pcr
assay
human
coronaviru
human
bocaviru
influenzavirusc
unfortun
number
pathogen
detect
mng
current
lack
target
therapeut
develop
pharmacolog
cellbas
therapi
remain
prioriti
field
addit
studi
suggest
mani
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
immunosuppress
patient
suspect
noninfecti
pulmonari
syndrom
hepat
venoocclus
diseas
thrombot
microangiopathi
pulmonari
graftversushost
diseas
studi
sever
strength
first
optim
identif
aspergillu
rna
contextu
aspergillu
sequenc
read
compar
growth
cultur
bal
galactomannan
second
propos
logic
analyt
framework
rank
organ
abund
within
sampl
rel
sampl
framework
allow
us
rapidli
exclud
identifi
bacteria
third
provid
knowledg
first
evalu
pulmonari
microbiom
immunocompromis
children
pilot
studi
sever
limit
first
use
standard
zscore
use
deemphas
commonli
abund
organ
ie
spneumonia
may
overvalu
uncommon
pathogen
less
abund
transcript
ie
cmv
undervalu
frequent
encount
pathogen
ie
rhinoviru
addit
larger
studi
aim
quantifi
pulmonari
microbi
commun
immunocompromis
children
natur
improv
valu
zscore
analysi
second
mng
assay
identif
microbi
nucleic
acid
directli
confirm
presenc
viabl
live
organ
directli
implic
microb
contributor
pulmonari
diseas
exclud
less
abund
organ
potenti
contributor
pulmonari
diseas
order
optim
patient
outcom
advoc
ongo
multidisciplinari
collabor
intensivist
immunologist
oncologist
transplant
physician
infecti
diseas
physician
pulmonologist
bioinformatician
basic
scientist
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
summari
present
mng
assay
optim
evalu
pulmonari
microbiom
detect
potenti
pathogen
immunocompromis
children
assay
highli
sensit
reveal
rich
bacteri
fungal
viral
pulmonari
microbiom
identifi
potenti
pathogen
half
previous
neg
sampl
advanc
organ
detect
offer
potenti
earli
implement
target
therapi
possibl
improv
clinic
outcom
immunocompromis
children
invit
scientif
clinic
commun
particip
ongo
multicent
collabor
clinic
trial
aim
refin
emerg
technolog
http
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
